Clinical Trial Update: Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial investigating fenoldopam to prevent renal dysfunction in indomethacin-treated preterm infants was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury
• Patent Ductus Arteriosus

Drugs mentioned

• Fenoldopam (fenoldopam)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Patent Ductus Arteriosus (PDA), Acute Kidney Injury (AKI) | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2022-09-16